-- Earnings Flash (INMB) INMUNE BIO Reports Q2 Revenue $16,000
4:33PM ET 8/03/2022 MT Newswires...
Quotes Snapshot > INMB
INmune Bio Inc INMB:NASDAQ
Last Price$9.12NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/11/22
Today's Change-0.21(2.25%)
Bid (Size)$8.36 (3)
Ask (Size)$15.08 (1)
Day Low / High$9.05 - 9.74
Volume39.8 K
Read more news Recent News
INmune Bio Receives US Patent Covering Use of Central Nervous System Diseases Treatment
9:36AM ET 6/22/2022 MT NewswiresINmune Bio (INMB) said Wednesday that it has been issued a US patent covering the use of dominant negative tumor necrosis factor compositions by peripheral...
Sector Update: Health Care Stocks Returning to Positive Ground in Late Trade
4:01PM ET 5/24/2022 MT NewswiresHealth care stocks were narrowly higher this afternoon, with the NYSE Health Care Index climbing less than 0.1% and the SPDR Health Care Select Sector ETF...
View all Commentary and Analysis
INmune Bio, Inc's (INMB) CEO RJ Tesi on Q2 2022 Results - Earnings Call Transcript
9:55PM ET 8/03/2022 Seeking AlphaAlector, INmune Bio, Inflammation, And Alzheimer's Disease: One Piece Of The Puzzle
3:35PM ET 7/22/2022 Seeking AlphaINmune Bio: Possibly The Once In A Lifetime Dip
11:28AM ET 5/25/2022 Seeking AlphaINmune Bio's (INMB) CEO RJ Tesi on Q1 2022 Results - Earnings Call Transcript
1:39AM ET 5/08/2022 Seeking AlphaCompany Profile
Business DescriptionINmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL. View company web site for more details
| Address | 225 NE Mizner Boulevard Boca Raton, Florida 33432 |
| Phone | +1.858.964.3720 |
| Number of Employees | 3 |
| Recent SEC Filing | 08/04/2022 8-K |
| Chairman, President, Chief Executive Officer & CMO | Raymond J. Tesi |
| Chief Financial Officer, Secretary & Treasurer | David J. Moss |
| Chief Scientific & Manufacturing Officer | Mark Lowdell |
| Associate General Counsel | Joshua S. Schoonover |
Company Highlights
| Price Open | $9.38 |
| Previous Close | $9.12 |
| 52 Week Range | $4.63 - 30.37 |
| Market Capitalization | $163.7 M |
| Shares Outstanding | 17.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/02/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.86 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -9,233.15% |
| Return on Equity | -41.87% |
Analyst Ratings as of 05/23/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |